Neuphoria Explores Sale Options After Drug Trial Failure
Neuphoria Therapeutics initiates strategic review following failed clinical trial. Lynx1 Fund offers $5.20/share buyout as biotech company explores merger and partnership options.
/ 914 items
#Healthcare↓
AnaptysBio ends UC trial, advances RA program, plans 2026 split
Rosnilimab UC trial discontinued after failing efficacy endpoint. AnaptysBio advances RA program & ANB033 (CeD). Plans firm for 2026 corporate split.
Surgery Partners Stock Plunges 25% on Lowered Revenue Outlook
Surgery Partners shares hit five-year low after cutting full-year guidance due to weaker patient volumes and insurance payment trends in Q3 2025.
H.C. Wainwright Raises Vera Therapeutics Price Target to $90 After ORIGIN 3 Data
Vera Therapeutics has submitted its application for atacicept, a potential breakthrough IgAN treatment that successfully reduced proteinuria in the Phase 3 ORIGIN 3 trial.
FDA Clears Path for Key Phase 3 Trial of Lacutamab in CTCL Treatment
Innate Pharma is moving forward with the TELLOMAK 3 trial for lacutamab in advanced cutaneous T-cell lymphomas (CTCL), including Sézary syndrome (SS) and Mycosis fungoides (MF).
Eli Lilly Signs $475M Deal with MeiraGTx for Vision-Restoring Gene Therapy
Eli Lilly partners with MeiraGTx in a $475M deal for a breakthrough gene therapy, AAV-AIPL1, designed to restore vision in children born legally blind.